Molecular Diagnostics Market to Grow at 13.1% CAGR Through 2030

"Driven by Advances in Genetic and Cancer Testing, Molecular Diagnostics Emerges as a Critical Tool for Early Disease Detection and Risk Prediction"

Boston, Oct. 22, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Molecular Diagnostics: Technologies and Global Markets” is projected to grow from $23 billion in 2025 to $42.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% during the forecast period of 2025 to 2030.

This report offers a detailed analysis of the global molecular diagnostics market, segmented by product and service type, technology, application, and region. It explores key technologies such as PCR and NGS, and applications including infectious diseases and oncology. The study highlights regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, while also examining ESG initiatives, emerging technologies, and patents. It concludes with insights into the competitive landscape and profiles of leading manufacturers, providing a strategic overview of market dynamics and vendor approaches.

This report is highly relevant now due to the increasing reliance on molecular diagnostics in managing infectious disease outbreaks and cancer detection. The growing demand for precise and rapid testing has accelerated the adoption of advanced technologies like NGS and liquid biopsy, which expand the scope and effectiveness of molecular diagnostics. Additionally, favorable reimbursement policies in the U.S. and Europe are encouraging broader use of these diagnostic tools, making them more accessible and driving market growth.

The factors driving the market’s growth include:

Increasing Prevalence of Infectious Diseases: The global rise in infectious diseases such as COVID-19, HIV, and influenza has boosted the demand for molecular diagnostics. These technologies offer fast, accurate detection of pathogens, enabling timely treatment and containment, especially during outbreaks and pandemics.

Growing Need for Early Detection of Chronic Diseases: Chronic conditions like cancer and cardiovascular diseases benefit greatly from early diagnosis, which molecular diagnostics can provide through genetic and biomarker testing. Early detection improves patient outcomes and reduces long-term healthcare costs, making it a vital tool in preventive medicine.

Point-of-Care Testing: Point-of-care molecular diagnostics allow testing to be done directly at the patient’s location, delivering rapid results without the need for centralized labs. This is especially useful in emergency settings, rural areas, and during public health crises.

Companion Diagnostics for Targeted Therapies: Companion diagnostics are used to determine a patient’s suitability for specific treatments, especially in personalized medicine. By identifying genetic markers or mutations, these tests help tailor therapies to individual patients, enhancing treatment effectiveness and minimizing side effects.

Request a sample copy of the global market for molecular diagnostics report.

Report Synopsis

Interesting fact:

• The applications of molecular testing are expanding to new disease areas, such as transplantation, cardiovascular and neurological conditions. Molecular testing can enable the possibility of non-invasive testing for cancer diagnosis.

Emerging startups:

• Sherlock Biosciences, Inc.
• binx health
• Diasorin S.p.A.
• Tempus AI
• Guardant Health
• Delfi Diagnostics Inc.

The report addresses the following questions:

1. What are the projected size and growth rate of the market?

• The global molecular diagnostics market was valued at $20.3 billion in 2024 and is expected to reach $42.6 billion by the end of 2030 at a CAGR of 13.1%.

2. What factors are driving the growth of the market?

• The increasing need for the early diagnosis of cancer and rare diseases and the growing prevalence of infectious diseases drive market growth.

3. What are the key challenges and opportunities of the market?

• The stringent regulations and the high costs of equipment and testing are challenges to market growth during the forecast period. Developing PoC tests and focusing on companion diagnostics creates new market prospects.

• What market segments are covered in the report?
• The market is segmented based on technology, product and service, application, and region. The report analyzes global revenue ($ million) for the base year 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented based on product and service type, application, technology, and region. The market is segmented into consumables, instruments, software, and services based on product and service type. The market is segmented based on technology into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ICH), microarrays, and others. The market is further segmented based on application into infectious diseases, oncology, pre-and post-natal testing, identity/paternity testing, and others. The regions covered in this study include North America, Europe, Asia-Pacific, and the Rest of the World. The report also discusses patents and emerging technologies related to the market.

4. Which technology type segment will be dominant through 2030?

• PCR will dominate the molecular diagnostics market through the forecast period.

5. Which region has the largest market share?

• North America accounted for 41.8% of the market in 2024.

Market leaders include:

• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BD
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• DANAHER CORP.
• EXACT SCIENCES CORP.
• F. HOFFMANN-LA ROCHE LTD.
• HOLOGIC INC.
• ILLUMINA INC.
• MYRIAD GENETICS INC.
• QIAGEN
• REVVITY
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.

Related reports:

Oncology Diagnostics: Global Markets: This report provides a detailed analysis of the oncology diagnostics market, covering its segmentation by technology, cancer type, end user, and region. It explores market dynamics such as growth drivers, challenges, and opportunities, and includes profiles of leading companies and their revenues, product portfolios, and recent developments.

Global Colorectal Cancer Screening and Diagnostics Market: This report offers an overview of the colorectal cancer screening and diagnostic testing service market, highlighting trends, emerging technologies, and market drivers, challenges, and opportunities. It includes segmentation by region and provides financial and strategic insights into major companies like Fujifilm, Olympus, and Exact Sciences. The analysis supports informed decision-making by presenting market forecasts and in-depth profiles of leading service providers and manufacturers.

Purchase a copy of the report direct from BCC Research.

For further information on any of these reports or to make a purchase, contact info@bccresearch.com.    

About BCC Research

BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

BCC Research

Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, U.S.
Email: info@bccresearch.com
Phone: +1 781-489-7301

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.